Macro Dynamics - The People's Bank of China reported that as of the end of May, the broad money supply (M2) stood at 325.78 trillion yuan, reflecting a year-on-year growth of 7.9% [1] - The narrow money supply (M1) was 108.91 trillion yuan, with a year-on-year increase of 2.3% [1] - The currency in circulation (M0) reached 13.13 trillion yuan, showing a year-on-year growth of 12.1% [1] - A net cash injection of 306.4 billion yuan occurred in the first five months of the year [1] Automotive Industry - Eight departments, including the Ministry of Industry and Information Technology, are soliciting public opinions on the "Automotive Data Export Security Guidelines (2025 Edition)" [2] - Automotive data processors must declare data export security assessments under specific conditions, such as providing important data to overseas entities or exceeding certain thresholds of personal information [2] Employment and Pension - The Ministry of Human Resources and Social Security clarified that the location for receiving basic pension benefits for individuals with cross-province employment depends on where their pension insurance relationship is registered [3] - Three scenarios were outlined for pension distribution based on the location of the insurance relationship and duration of contributions [3] Real Estate Policy - Guangzhou has optimized its real estate policies by fully canceling purchase, sale, and price restrictions, as well as lowering down payment ratios and interest rates [4][5] - The city plans to invest 100 billion yuan in the renovation of urban villages and old residential areas by 2025, with over 150 old residential area renovations and more than 9,000 old elevators updated [5] Company Dynamics - Nezha Automobile's parent company, Hozon New Energy Automobile Co., has entered bankruptcy reorganization, with management by Zhejiang Zicheng Law Firm [16] - Tencent has no plans to acquire Nexon, as confirmed by sources close to the company [17] - AstraZeneca announced the launch of Truqap® in China, providing a new treatment option for HR-positive advanced breast cancer patients [17]